Recent Updates
Recently added Catalysts
ALT

Altimmune Launches Clinical Trial of T-COVID, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19

Monday, June 1, 2020 1 min read
Key Takeaway: Altimmune Launches Clinical Trial of T-COVID, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19

Full Press Release Details

Altimmune Launches Clinical Trial of T-COVID, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19.
Tags: ALT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 1, 2020